GT200700014A - Monohidrato de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que lo contienen - Google Patents

Monohidrato de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que lo contienen

Info

Publication number
GT200700014A
GT200700014A GT200700014A GT200700014A GT200700014A GT 200700014 A GT200700014 A GT 200700014A GT 200700014 A GT200700014 A GT 200700014A GT 200700014 A GT200700014 A GT 200700014A GT 200700014 A GT200700014 A GT 200700014A
Authority
GT
Guatemala
Prior art keywords
monohidrate
rimonabant
pharmaceutical compositions
compositions containing
preparation procedure
Prior art date
Application number
GT200700014A
Other languages
English (en)
Inventor
Oliver MONNIER
Gerard Coquerel
Baptiste Fours
Helene Duplaa
Philippe Ochsenbein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37075667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200700014(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200700014A publication Critical patent/GT200700014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA FORMA CRISTALINA DEL MONOHIDRATO DE RIMONABANT CUYA DENOMINACIÓN COMÚN INTERNACIONAL ES N-PIPERIDINO-5-(4-CLOROFENIL)-1-(2,4-DICLOROFENIL)-4-METILPIRAZOL-3-CARBOXAMIDA, PROCEDIMIENTOS PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN. T2007
GT200700014A 2006-02-08 2007-02-06 Monohidrato de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que lo contienen GT200700014A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0601253A FR2897060B1 (fr) 2006-02-08 2006-02-08 Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
GT200700014A true GT200700014A (es) 2007-09-19

Family

ID=37075667

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200700014A GT200700014A (es) 2006-02-08 2007-02-06 Monohidrato de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que lo contienen

Country Status (20)

Country Link
US (1) US20090048449A1 (es)
EP (1) EP1984341A1 (es)
JP (1) JP2009526025A (es)
KR (1) KR20080093042A (es)
CN (1) CN101405271A (es)
AR (1) AR059327A1 (es)
AU (1) AU2007213649A1 (es)
BR (1) BRPI0707711A2 (es)
CA (1) CA2641494A1 (es)
DO (1) DOP2007000023A (es)
EA (1) EA200870236A1 (es)
FR (1) FR2897060B1 (es)
GT (1) GT200700014A (es)
IL (1) IL192963A0 (es)
MA (1) MA30312B1 (es)
NO (1) NO20083521L (es)
TW (1) TW200804343A (es)
UY (1) UY30137A1 (es)
WO (1) WO2007090949A1 (es)
ZA (1) ZA200806713B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057144A4 (en) * 2006-09-01 2010-06-02 Hetero Drugs Ltd NEW POLYMORPHIC FROM RIMONABANT
WO2008056377A2 (en) * 2006-11-06 2008-05-15 Cadila Healthcare Limited Polymorphic forms of rimonabant
HUE043014T2 (hu) * 2014-12-08 2019-07-29 Crystal Pharmatech Co Ltd Valzartánt és AHU 377-et tartalmazó trinátrium szupramolekuláris komplex kristályos formái, és az ezekhez tartozó eljárások

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
JP4746931B2 (ja) * 2005-07-22 2011-08-10 株式会社日立製作所 フラットディスプレイパネルモジュール及びフラットディスプレイ装置
EP2057144A4 (en) * 2006-09-01 2010-06-02 Hetero Drugs Ltd NEW POLYMORPHIC FROM RIMONABANT
WO2008035023A1 (en) * 2006-09-19 2008-03-27 Cipla Limited Polymorphs of rimonabant

Also Published As

Publication number Publication date
KR20080093042A (ko) 2008-10-17
EP1984341A1 (fr) 2008-10-29
BRPI0707711A2 (pt) 2011-05-10
TW200804343A (en) 2008-01-16
JP2009526025A (ja) 2009-07-16
ZA200806713B (en) 2009-10-28
UY30137A1 (es) 2007-09-28
DOP2007000023A (es) 2008-02-15
NO20083521L (no) 2008-10-24
EA200870236A1 (ru) 2009-02-27
WO2007090949A1 (fr) 2007-08-16
AR059327A1 (es) 2008-03-26
CA2641494A1 (fr) 2007-08-16
CN101405271A (zh) 2009-04-08
FR2897060B1 (fr) 2008-07-25
MA30312B1 (fr) 2009-04-01
US20090048449A1 (en) 2009-02-19
AU2007213649A1 (en) 2007-08-16
IL192963A0 (en) 2009-02-11
FR2897060A1 (fr) 2007-08-10

Similar Documents

Publication Publication Date Title
UY38258A (es) Moléculas que tienen utilidad plaguicida, y composiciones y procesos, relacionados con ellas
AR121635A2 (es) Nueva sal y formas cristalinas
HN2011000699A (es) El compuesto (s)-1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de 2-amida del acido pirrolidin-1,2-dicarboxilico en forma libre o de sal y composiciones y composicion farmaceutica que lo contiene.
HN2012001162A (es) Triazolopiridinas
DOP2011000097A (es) Arilpirrolidinas pesticidas
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
CR11267A (es) Preparacion solida que contiene alogliptina y clorhidrato de metformina
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
UY30320A1 (es) Formas polimorficas de 1-((4-metil-quinazolin-2-il)metil)--3-metil-7-(2-butin-1-il)-8-(3-(r)-amino-piperidin-1-il)-xantina, preparaciones, composiciones de preparacion y aplicaciones de las mismas.
MX2010002285A (es) Combinaciones de principios activos con propiedades insecticidas y acaricidas.
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
CU20120002A7 (es) DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
CO6321158A2 (es) Formulacion oral
CL2009000256A1 (es) Imidazolinas fenil sustituidas, composicion farmaceutica que contenga estos compuestos y su uso en el sindrome metabolico, obesidad, diabetes, sindrome de stein-leventhal, transtornos del snc, esquizofrenia, alzheimer, dependencia al alcohol y dependencia a la nicotina.
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada
DOP2006000248A (es) Acido 1-(1-(2-etoxietil)-3-etil-7-(4-metilpiridin-2-ilamino)-1h- pirazolo[4,3-d]pirimidin-5-il)piperidina-4-carboxílico y las sales del mismo.
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
CL2010001463A1 (es) Uso de una composicion farmaceutica solida que comprende 2-amino-2-(2-(a-alquil-c2-20-fenil)etil)propan)-1,3-diol (fty720) para preparar un medicamento util en el tratamiento, prevencion o retraso de esclerosisi multiple en niños y el kit farmaceutico que la contine.
GT200700014A (es) Monohidrato de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que lo contienen
GT201200017A (es) Preparacion de (r) y (s) - (3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino-6-metoxifenil)-1-(2,3-dihidroxipropil) ciclopropan-1-sulfonamida y derivados protegidos de los mismos:
CR20110332A (es) Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il)metanona-n-carboxamida
UY30861A1 (es) Formas solidas y cristalinas de rimonabant, procesos para su preparacion y composicion farmacéutica que las contienen